OncoZenge AB (publ)

OM:ONCOZ Stock Report

Market Cap: SEK 45.9m

OncoZenge Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Stian Kildal

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.3yrs
CEO ownership2.3%
Management average tenureno data
Board average tenureless than a year

Recent management updates

Recent updates

CEO

Stian Kildal (48 yo)

1.3yrs

Tenure

Mr. Stian Kildal is Chief Executive Officer of OncoZenge AB (publ) from September 13, 2023.

Board Members

NamePositionTenureCompensationOwnership
Stephen T. Sonis
Member of Advisory Boardless than a yearno datano data
Christoph Nowak
Independent Directorless than a yearno datano data
Niclas Holmgren
Independent Director1.3yrsno data10.9%
SEK 5.0m
Pooja Patel
Member of Advisory Boardless than a yearno datano data
Daniel Ehrenstrahle
Independent Chairman of the Boardless than a yearno datano data
Paolo Bossi
Member of the Advisory Boardless than a yearno datano data

1.0yrs

Average Tenure

38yo

Average Age

Experienced Board: ONCOZ's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 03:40
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OncoZenge AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kevin SuleRedeye